#pneumonia vaccine market share | Explore Tumblr Posts and Blogs

ramkumarss · 1 year

Text

Pneumonia Vaccine Market Growing at a CAGR of 5.6% | 2023-29

Pneumonia Vaccine Market Report provides an exhaustive analysis of the growth drivers, current trends, restraining forces, and opportunities present in the market.

The global Pneumonia vaccine market size was valued at USD 8.4 billion in 2022 and is poised to grow at a significant CAGR of 5.6% during the forecast period 2023-29. It also includes market size and projection estimations for each of the five major regions from 2023 to 2029. The research report includes historical data, trending features, and market growth estimates for the future. Furthermore, the study includes a global and regional estimation and further split by nations and categories within each region. The research also includes factors and barriers to the Pneumonia vaccine market growth, as well as their impact on the market's future growth. The report gives a comprehensive overview of both primary and secondary data.

View the detailed report description here - https://www.precisionbusinessinsights.com/market-reports/global-pneumonia-vaccine-market

The global Pneumonia vaccine market segmentation:

1) By Product Type : Prevnar 13, Synflorix, and Pneumovax 23.

2) By Dosage : Single Dose Vial and Pre-filled Syringe.

3) By End User : Child, Adult and Geriatric.

4) By Vaccine Type : Pneumococcal Conjugate Vaccine, and Pneumococcal Polysaccharide Vaccine

The primary factors of the Pneumonia vaccine market drivers are the Surge in prevalence of pneumonia across the globe. The Pneumonia vaccine market report helps to provide the best results for business enhancement and business growth. It further helps to obtain the reactions of consumers to a novel product or service. It becomes possible for business players to take action for changing perceptions. It uncovers and identifies potential issues of the customers. It becomes easy to obtain the reactions of the customers to a novel product or service. It also enlightens further advancement, so it suits its intended market.

The Pneumonia vaccine marketresearchreport gives a comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America was the largest region in the Pneumonia vaccine market report, accounting for the highest share in 2022. It was followed by Asia Pacific, and then the other regions. Request sample report at - https://www.precisionbusinessinsights.com/request-sample/?product_id=46307

The important profiles and strategies adopted by Pneumonia vaccine market key players are GlaxoSmithKline plc, Pfizer Inc, CSL Ltd, Merck & Co., Inc., Serum Institute of India Pvt. Ltd, Sanofi Pasteur Inc., covered here to help them in strengthening their place in the market.

About Precision Business Insights: We are a market research company that strives to provide the highest quality market research insights. Our diverse market research experts are enthusiastic about market research and therefore produce high-quality research reports. We have over 500 clients with whom we have a good business partnership and capacity to provide in-depth research analysis for more than 30 countries. In addition to deliver more than 150 custom solutions, we already have accounts with the top five medical device manufacturers.

Precision Business Insights offers a variety of cost-effective and customized research services to meet research requirements. We are a leading research service provider because of our extensive database built by our experts and the services we provide.

Contact:

Mr. Satya

Precision Business Insights | Toll Free: +1 866 598 1553

Email: [email protected] Kemp House, 152 – 160 City Road, London EC1V 2NX Web: https://precisionbusinessinsights.com/ | D U N S® Number: 852781747

#pneumonia vaccine market size #pneumonia vaccine market share #pneumonia vaccine market growth #pneumonia vaccine market trends #pneumonia vaccine market outlook #pneumonia vaccine market dynamics

0 notes

darkmaga-retard · 1 day

Text

ICAN’s attorneys obtained documents related to the widely reported May 2023 “outbreak” of measles in Maine. As it turns out, test results from the CDC confirmed that the measles case was “consistent with vaccine strain,” meaning there was no “outbreak” and, instead, it was the vaccine that caused the child’s rash.

Lead Counsel, Aaron Siri, Esq. lays out the details here:

On May 5, 2023, the Maine CDC reported that a child had “tested positive” for measles. News outlets immediately began fearmongering, hinting that the “outbreak” was due to low vaccination rates:

“Measles can be serious for anyone…” (Maine CDC Facebook Page)

“In severe cases, measles can cause pneumonia, brain swelling and death.” (Bangor Daily News)

“The CDC says roughly one to three of every 1,000 children infected with measles die.” (USA Today) Note: the death rate is actually more like 1 in 500,000.

“Measles was declared eliminated from the US in 2000… But vaccination rates in the US have dropped in recent years, sparking new outbreaks.” (CNN)

“Anyone who is not immunized or does not know their measles immunization status should get vaccinated.” (Maine CDC Press Release)

The Maine CDC reported that even though the child had received a dose of the measles, mumps, and rubella (MMR) vaccine, it was “considering the child to be infectious out of an abundance of caution.” In the meantime, the Maine CDC indicated it had sent a specimen to CDC headquarters to determine the specific strain of measles; however, it did not mention how the child would have been exposed to the wild strain of measles, such as international travel, nor did it share how recently the child may have received the vaccine.

According to a WHO report, about 2% of those who receive the measles vaccine develop a rash, called VARI (vaccine-associated rash illness). In fact, one study recommends assuming the rash is vaccine-caused and that “testing should only be considered if exposure to the wild-type (not vaccine-strain) virus is strongly suspected.”

So, it is unclear why the Maine CDC raised the alarm and then took so long to confirm the specific strain. The child was diagnosed on May 3, but it took the Maine CDC five days to ship the sample to the CDC. It then took the CDC seven days to report the results and for the Maine CDC to announce the child was not infectious.

ICAN, through its attorneys, requested relevant records and received them. Incredibly, they reveal that the positive measles test was “[c]onsistent with vaccine strain,” which is apparently an “acceptable” form of measles because, as the Maine CDC announced, the strain that the child tested positive for was not considered “an infectious strain of the virus,” despite causing traditional symptoms of the disease. Decidedly absent from Maine’s announcement was the fact that the child got measles as a result of the vaccine. Maine and the CDC simply hid this fact from the public.

Maine’s actions make sense, however, when considering that it may have just been following a CDC marketing presentation which states that the perfect “recipe” for creating demand for vaccines “requires creating concern, anxiety, and worry” by, for example, having medical experts and public health authorities “state concern and alarm (and predict dire outcomes)” and show “[v]isible/tangible examples of the seriousness of the illness (e.g., pictures of children, families of those affected coming forward) and people getting vaccinated (the first to motivate, the latter to reinforce)” — all things we saw implemented during this “outbreak.”

ICAN will continue to follow-up on reported outbreaks across the country. In the meantime, catch up on some of ICAN’s additional work on vaccine policy:

ICAN’S MONUMENTAL MISSISSIPPI WIN

FDA CONTINUES TO AVOID ICAN’S PETITION TO SUSPEND THE IPOL POLIO VACCINE FOR CHILDREN

FEDERAL GOVERNMENT DROPS COVID-19 VACCINE TRAVEL MANDATE ON SAME DAY IT WAS DUE TO RESPOND TO ICAN’S LEGAL CHALLENGE

ICAN-FUNDED LAWSUIT PROHIBITING ANY LOCAL VACCINE MANDATES WINS FINAL BATTLE; SETS CALIFORNIA PRECEDENT

IN CASE YOU MISSED IT: ICAN-FUNDED SUIT AGAINST OSHA VACCINE MANDATE PREVAILS

3 notes · View notes

shubhampawrainfinium · 1 month

Text

Can the 23-Valent Pneumococcal Vaccine Market Address Global Health Challenges?

Introduction

The 23-valent pneumococcal polysaccharide vaccine (PPSV23) is crucial in preventing pneumococcal disease caused by 23 types of Streptococcus pneumoniae bacteria. This vaccine is particularly important for vulnerable populations, including the elderly and individuals with certain health conditions. This report offers a comprehensive analysis of the market for PPSV23, including key drivers, challenges, and opportunities.

Market Dynamics

Drivers:

Increased Awareness: Growing awareness of pneumococcal disease and its prevention among healthcare providers and patients boosts vaccine uptake.

Government Recommendations: Public health guidelines and vaccination programs support the widespread use of PPSV23.

Aging Population: The increasing elderly population, who are at higher risk of pneumococcal infections, drives demand for the vaccine.

Challenges:

High Costs: The cost of vaccines can be a barrier to widespread vaccination, particularly in low-income regions.

Vaccine Hesitancy: Misconceptions and resistance to vaccination can impact vaccine uptake rates.

Regulatory Hurdles: Navigating regulatory requirements and securing approvals can be complex and time-consuming.

Opportunities:

Expansion into Emerging Markets: Growing healthcare infrastructure in developing regions presents opportunities for increasing vaccine coverage.

Public Health Initiatives: Increased funding and initiatives aimed at improving vaccination rates can drive market growth.

Innovations in Vaccine Development: Advances in vaccine technology and formulation may enhance efficacy and reduce costs.

Regional Analysis

North America:

Market Overview: High demand due to comprehensive vaccination programs and strong healthcare infrastructure.

Trends: Government recommendations and public health campaigns drive widespread vaccine use.

Europe:

Market Overview: Strong market with increasing vaccination coverage driven by public health policies.

Trends: Emphasis on preventive healthcare and vaccination programs supports market growth.

Asia-Pacific:

Market Overview: Emerging market with growing demand due to increasing healthcare access and awareness.

Trends: Expanding vaccination programs and healthcare infrastructure contribute to market growth.

Sample pages of Report: https://www.infiniumglobalresearch.com/form/407?name=Sample

Market Segmentation

By Application:

Elderly Population: Primary target group for pneumococcal vaccination to prevent infections and complications.

High-Risk Groups: Includes individuals with chronic conditions or compromised immune systems.

By Region:

North America

Europe

Asia-Pacific

Latin America

Middle East & Africa

Competitive Landscape

Market Share of Large Players: Major pharmaceutical companies dominate the market, leveraging extensive distribution networks and established reputations.

Price Control: Large players influence pricing strategies and market dynamics.

Small and Mid-Size Companies: These companies may offer alternative vaccines or contribute to innovation in vaccine development.

Key Players:

Pfizer

Sanofi Pasteur

Merck & Co.

GlaxoSmithKline

Report Overview : https://www.infiniumglobalresearch.com/market-reports/global-23-valent-pneumococcal-polysaccharide-vaccine-market

Future Outlook

New Product Development: Ongoing R&D efforts may lead to the development of enhanced vaccines with broader coverage and improved efficacy.

Targeting Vulnerable Populations: Focus on increasing vaccination rates among high-risk and elderly populations through targeted public health campaigns.

Conclusion

The 23-valent pneumococcal polysaccharide vaccine market is driven by public health initiatives, increasing awareness, and a growing elderly population. Companies must address challenges related to cost and vaccine hesitancy while leveraging opportunities in emerging markets and advancements in vaccine technology.

0 notes

researchinsights · 3 months

Text

The global pneumonia therapeutics market is projected to reach USD 14,956.4 million in 2023, registering at a Compound Annual Growth Rate (CAGR) of 8.7% during the forecast period 2024-2030. The growth of the marketis majorly driven by the rising number of ongoing clinical trials for vaccine development and drug molecules

#Pneumonia Therapeutics Market #Pneumonia Therapeutics Market Size #Pneumonia Therapeutics Market Share

0 notes

bommagoni · 5 months

Text

Pneumonia Vaccine Market Size, Share, Trends, Forecast 2030

#Pneumonia Vaccine Market

0 notes

omkarpatel · 9 months

Text

Adult Vaccines Market is Estimated to Witness High Growth Owing to Opportunity of Reduction in Disease Burden

Adult vaccines are primarily used in immunizing adults against diseases such as hepatitis, influenza, pneumonia and herpes zoster. These vaccines help protect individuals against severe illnesses and reduce the disease burden. Adult vaccines are usually prescribed for individuals above 18 years of age or for those entering adulthood. They are important in reducing risks of vaccine preventable diseases and controlling epidemic outbreaks. The global Adult Vaccines Market is estimated to be valued at US$ 16,790.11 Mn in 2023 and is expected to exhibit a CAGR of 7.1% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Market Opportunity: The opportunity for reduction in disease burden is expected to drive significant growth of the adult vaccines market. Preventing diseases through vaccination can significantly reduce illness, disability and mortality among adults. Widespread adult vaccination programs can substantially lower the burden of many vaccine-preventable diseases globally. For instance, vaccination against influenza and pneumonia is crucial to protect adults from severe complications arising from these conditions. These vaccines can prove beneficial in reducing hospitalization, medical costs and loss of productivity associated with such diseases. Similarly, vaccination of adults against hepatitis B and herpes zoster significantly cuts down the risk of chronic liver disease and painful complications of shingles later in life. Effective vaccination coverage in older adults thus presents a major market opportunity to lower disease prevalence rates. This in turn is projected to augment demand for adult vaccines over the forecast period. Porter's Analysis Threat of new entrants: Low- Medium. Significant capital is required to conduct R&D and bring new vaccines to market. Regulatory barriers also exist. Bargaining power of buyers: Medium. A large customer base of healthcare providers and govts who purchase vaccines. Market consolidated with few major players. Bargaining power of suppliers: Low. Major pharma companies control intellectual property and production. Suppliers have less influence on prices. Threat of new substitutes: Low. Limited substitute prevention measures compared to effectiveness of vaccines. Competitive rivalry: High. Major players compete on innovation, pricing and market share. SWOT Analysis Strengths: Growing aging population worldwide increases market. Vaccines save on long term healthcare costs. Weaknesses: Low awareness in developing nations. Vaccine hesitancy and refusals impact uptake rates. Opportunities: Development of immunotherapies and combo vaccines presents scope. Untapped potential in certain countries. Threats: Stringent regulations delay products. Outbreaks can impact demand prognosis. Vaccine price control policies hurt revenue. Key Takeaways The global Adult Vaccines market is expected to witness high growth over the forecast period of 2023 to 2030. The market size is projected to grow from US$ 16,790.11 Mn in 2023 to US$ 33,678.42 Mn by 2030 at a CAGR of 7.1%. Key players operating in the adult vaccines market are GlaxoSmithKline Plc, Merck & Co., Sanofi Pasteur, Pfizer Inc., CSL Limited, Johnson & Johnson, Serum Institute of India, Medimmune, and AstraZeneca Plc. Major players are focused on expanding their portfolio through acquisitions and new product launches.

#healthcare

0 notes

1-2-3-4-4498-0 · 11 months

Text

Solar Energy and Health: The Vaccine Refrigeration Revolution

Solar-powered vaccine refrigerator Market are designed to store vaccines and other medical products at a stable temperature to ensure they do not degrade. In developing countries with a sunny climate, solar-powered vaccine refrigerators are common. Many vaccines must be stored at low temperatures, some below -15 °C, and others between 2 and 8 °C. If vaccines are not stored correctly, they can lose their effectiveness.

The ideal temperature for storing vaccines in the ILR is +2 degrees to + 8 degrees According to the Centre for Disease Control, failure to adhere to recommended specifications for storage and handling of immunobiology’s can reduce or destroy their potency, resulting in inadequate or no immune response in the recipient. Maintenance of vaccine quality is the shared responsibility of all handlers of vaccines from the time a vaccine is manufactured until administration. According to the Immunization Action Coalition, all vaccines should be stored in a refrigerator or freezer that is designed specifically for the storage of biologics or, alternatively, in a separate dedicated unit.

A dorm-style combination refrigerator-freezer unit with just one exterior door has been shown to be unacceptable no matter where the vaccine was placed inside the unit. Stand-alone refrigerator or freezer units are best for storage needs. With retail pharmacies now playing a major role in pneumonia, influenza and shingles immunization programs, the value of critical vaccines being stored in pharmacy refrigerators has reached a new high. In fact, it is not uncommon for many pharmacies to now have over $100,000 of product in a single refrigerator during peak seasons.

COVID-19 Impact analysis

The COVID pandemic, and now finally, the vaccination push across the world against the disease has put the spotlight firmly on the role distributed solar products, particularly Solar refrigeration could play

Rockwell Industries Ltd, a commercial cold chain appliances manufacture, Thursday launched its new product called ‘Chillermill’ here. The product is both a freezer and chiller useful to store COVID-19 vaccine at the required temperatures.

The Vaccine Alliance — began buying and installing solar-powered fridges to store vaccines throughout the region. The idea would be a gamechanger for regional and district health workers who often struggle to carry out routine immunizations for children in places with unreliable electricity and cold storage facilities.

Top Impacting Factors

Solar refrigeration was an encouraging development in the early 1980s, providing a substitute for the absorption technology to meet cold chain requirements in remote areas with finite or no electric power. At present, various solar refrigeration models prequalified by the World Health Organization (WHO) are in use. A fresh approach in solar-based refrigeration has emerged, wherein the newly designed solar refrigerator has gotten rid of the need for high priced energy storage batteries employed to power solar refrigerators. This technology called solar direct drive technology uses solar energy to directly freeze water or other cold storage material (for instance, refrigerant) and then, uses the energy stored in the frozen bank to keep the refrigerator cold during nights and rainy days when the upcoming solar energy is not within easy reach.

Market Trends

Solar-powered vaccine refrigerators, also called off-grid photovoltaic (PV) systems, are put to use to maintain a continues temperature suitable for storing vaccines in clinics

In solar-powered vaccine refrigerators, photovoltaic modules transmute the solar energy directly into electricity, which is further employed to power the compressor of the vaccine refrigerator. On the other hand, rechargeable batteries are also used to store electric energy. The charge controller regulates the flow of electricity to protect batteries from over-discharging and overcharging.

Use of solar-based refrigeration for vaccine storage is a major development in the global health care industry. It is useful for remote areas, where electricity is not available in sufficient amounts. The global health care industry has witnessed rapid growth in the recent years. Growing elderly population worldwide, high prevalence of chronic diseases, and advancements in innovative digital technologies are some of the major factors driving the global health care industry.

Electricity rates are inherently turbulent. They fluctuate seasonally, monthly, and annually. Over the last decade, electricity prices had increased enormously and they are poised to increase even more during the forecast period. This, in turn, is projected to rise the demand for use of the solar technology for storage of vaccines in the near future.

There exists high demand for exploration of sustainable and clean sources for energy, as the world tries to limit emissions and targets to reach net zero carbon emissions

Government support in the form of favorable initiatives has driven usage of the solar technology over the last few years. This is estimated to be a major factor driving the global solar-powered vaccine refrigerator market during the forecast period. For instance, the Solar Energy Corporation of India (SECI) has passed a tender, wherein the government would be offering 30% subsidy to the social sector, the residential sector, private and not-for-profit organizations in the field of education, and health care institutions.

Key Benefits of the Report

This study presents the analytical depiction of the Solar-powered vaccine refrigerator industry along with the current trends and future estimations to determine the imminent investment pockets.

The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the Solar-powered vaccine refrigerator market share.

The current market is quantitatively analyzed from 2020 to 2030 to highlight the Solar-powered vaccine refrigerator market growth scenario.

Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.

The report provides a detailed Solar-powered vaccine refrigerator market analysis based on competitive intensity and how the competition will take shape in coming years.

Key Market Players : ACMAS Technologies (P) Ltd KYOCERA Corporation, QINGDAO HERALD CRYOGENIC TECHNOLOGY CO., LTD, Godrej Appliances,, Qingdao Amed Commercial Refrigeration Equipment Co., Ltd, RuthurEnergy Limited, Meditech Technologies India Private Limited, Sure Chill, Haier, Vestfrost Solutions,, Neumann & Miller, Dulas Ltd., Renaissance Energy Systems, Sundanzer

#Solar #powered #vaccine #refrigerator #Market

0 notes

meghanester · 11 months

Text

Albumin Market Size, Growth with a CAGR of ~6% During 2023-2035 and Attain ~USD 10 Billion by 2035

Research Nester’s recent market research analysis on “Albumin Market: Global Demand Analysis & Opportunity Outlook 2035” delivers a detailed competitors analysis and a detailed overview of the global albumin market in terms of market segmentation by type, grade, application, and by region.

Rise in the Number of Heart Operation Performed in the World to Promote Global Market Share of Albumin

The global albumin market is estimated to grow majorly on account of the increasing prevalence of diseases, that affects human organs and requires the surgery. For instance, Patients undergoing cardiac surgery may incur severe blood loss, demanding the replacement of electrolytes and blood-related materials. Therefore, rise in the number of cardiac surgeries will drive the demand for albumins. Every year, roughly 2 million individuals worldwide receive open-heart surgery in order to treat various cardiovascular conditions. On the other hand, it is expected that in the coming few years, over 50 million adults in the world will be suffering from chronic liver disease, since it occurrence rate has increase from 4.5% to 9.5% in the world wide population. Albumin is employed as a component in the removal of excess fluid from the abdomen in liver illnesses.

Get a Sample PDF Brochure: https://www.researchnester.com/sample-request-5035

Besides this, various development has taken place in albumin, which makes it suitable for treating or aiding the treatment of a wide range of diseases. For instance, some researchers have suggested in COVID-19 patients if albumin serum is injected at low levels. It helps identify patients who are at high risk of developing pneumonia or respiratory failure and patients who require longer stays at the hospital. Furthermore, the rising popularity of plant-based albumin has significant drive the industry’s expansion. Plant-based albumins enable adaptation and change in function. As a result, scientists are attempting to create novel plant-based albumins through genetic engineering or by optimizing natural sources.

Some of the major growth factors and challenges that are associated with the growth of the global albumin market are:

Growth Drivers:

Surge in the Cardiovascular Surgeries

Rising Use of Albumins in the Research and Development of Drug Delivery Systems

Challenges:

Many people have shown allergic reactions towards albumin and there are strict regulatory policies for approving the use of albumin are some of the major factors anticipated to hamper the global market size of albumin. Individuals with known allergies to albumin or other proteins are more prone to experience allergic responses. The symptoms range from, skin rashes to serious effects, like breathlessness, chest pain, and others. On the other hand, there are many substitutes present in the market which is also expected to impede market growth. Albumins face competition from various alternative products and technologies in different applications. Some of the tough competitors are synthetic polymers, hydroxyethyl starch (HES), recombinant proteins, human serum-derived proteins, nanoparticles, and liposomes.

Request for customization @ https://www.researchnester.com/customized-reports-5035

On the basis of application, the global albumin market is segmented into drug formulation & vaccines, therapeutics, research. The therapeutics segment is anticipated to bring in the most revenue by the end of 2035, with a considerable CAGR over the forecast period. The growth of the segment is credited to growing incidents involving severe burns and other injuries. Albumin is utilized as a plasma expander to restore and maintain intravascular volumes, which is lost due to severe burns. Furthermore, based on type, the market is further fragmented into recombinant albumin, human serum albumin, bovine albumin. Out of all, human serum albumin has shown tremendous growth and will be growing notably in the forecast period. The rising spending on the research and development of new drugs has boosted the demand for human serum albumin,

Furthermore, by the end of 2035, Europe is expected to control a significant share of the market. Improved understanding of the role of albumin in various conditions and the development of innovative therapies have increased the utilization of albumin in Europe. The advancements in medical technology and practices have expanded the application of albumins in healthcare. On the other hand, the rising prevalence of liver diseases, such as cirrhosis, hepatitis, and liver failure are also anticipated to boost the market growth in the region.

Obtain this Report @ https://www.researchnester.com/reports/albumin-market/5035

This report also provides the existing competitive scenario of some of the key players of the global albumin market which includes company profiling of Octapharma AG, Bio Med International Pvt. Ltd., Baxter, Apotex Inc., Novozymes, Mitsubishi Tanabe Pharma America Inc., Merck KGaA, Akron Biotech, Thermo Fisher Scientific, and Grifols, S.A

About Us

Research Nester is a leading service provider for strategic market research and consulting. We aim to provide unbiased, unparalleled market insights and industry analysis to help industries, conglomerates and executives to take wise decisions for their future marketing strategy, expansion and investment etc. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds. Our out of box thinking helps our clients to take wise decision in order to avoid future uncertainties.

Contact for more Info:

AJ Daniel

Email: [email protected]

U.S. Phone: +1 646 586 9123

U.K. Phone: +44 203 608 5919

#Albumin Market

0 notes

businessmagazineuae · 1 year

Text

Thoughtful Thursdays: Artificial Intelligence in Times of Pandemic

The world was taken by storm when covid 19 hit and started to “nurture” in December 2019. Not long after, the disease was spread to every city and every lane, leaving its strong, sharp effects on the healthcare industry. Early and quick detection of COVID-19 is a challenging task for the medical community, but it is also crucial in stopping the spread of the SARS-CoV-2 virus. Prior attestation of artificial intelligence (AI) in various fields of science has encouraged researchers to come up with stable and efficient solutions and further address this problem.

Artificial intelligence played a vital and independent role in countering corona while helping gain knowledge about necessary information such as vaccine distribution, hospital management, drug discovery, financial aid circulation, clinical data insights, and covid diagnosis.

AI can help in mitigating the impact of the lockdown and in actively responding to this crisis. A very important method to evaluate the effect is rapid and random widespread testing to understand the pattern and identify hotspot zones to quarantine affected people. Apps like Arogya Setu were introduced, which show much of the user’s risk factor depending on their movement and proximity to infected or at-risk people, based on location-based mobile data using Bluetooth for generating alerts. The app alerts are accompanied by instructions on how to self-isolate and what to do in case someone develops symptoms that they need help & support. Similarly, DRDO’s AI brains launched SAMPARC App, which had created a technology-focused solution to track patients who are under quarantine.

Also Read: AI: An Essential component For Security And Surveillance

The pandemic generated tons of data every day. Patient data, CT scans, MIT reports, chest X-rays, blood results, genetic data, and more. Human experts can barely scratch the surface of this data. Though fortunately enough, AI algorithms can process these insights at scale and analyze patterns to speed up diagnosis and give tips on vaccine development and treatment. Pharmaceutical firms, medical institutions, hospitals, and healthcare technology providers who adopt AI tools will boost both profits and market share.

The gold standard for diagnostic tests for COVID-19 is RT-PCR. However, RT-PCR does produce false negatives making it not the most trusted method to verify the disease. A study concluded that chests are far more sensitive to CT scans than to RT-PCR tests (98 vs. 71%, respectively). Using AI, we can train algorithms to produce and analyze chest computed tomography (CT) scans with vascular thickening, spider web, bilateral and GGO, and more complex patterns.

To add even further to this, we can make these algorithms with crazy high-end dimensional features even radiologists can’t handle, such as wavelet and texture information allowing pneumonia caused by covid to be distinguished early on and be given the right cure. Researchers have succeeded in developing a machine model that can diagnose corona from chest X-rays 10 times faster than human radiologists and up to 6% more accurately.

Kamal Kishor Singh is a technology enthusiast based in Muscat, Oman. He’s currently working as a Projects Delivery Manager for a major digital technology company in the Middle East.

With 18 years of experience in AI/ML based data analytics and automation, Kamal has developed several first-in-the-region digital products for government, banking, and telecom clients.

He has a keen interest in mentoring fresh talent and developing the tech start-up ecosystem in India and the Middle East.

Kamal has a bachelor’s degree in technology from NIT Allahabad and an MBA from IIM Calcutta.

Connect with Kamal on his LinkedIn

0 notes

marryp · 2 years

Link

0 notes

innovationtrends · 2 years

Text

Syringe Market Trends, Business Growth and Major Driving Factors 2027

According to our new market research study on “Syringe Market to 2027 – Global Analysis and Forecast – by Syringe Type, Application, Usability and End Use,” the market is expected to reach US$ 26,859.34 million by 2027 from US$ 12,649.46 million in 2019. The market is estimated to grow at a CAGR of 9.8% from 2020 to 2027. The report highlights trends prevailing in the market, and drivers and hindrances pertaining to the market growth.

Grab PDF to Know More (Including Table, Full TOC and Figures) @ https://www.theinsightpartners.com/sample/TIPRE00003521/

Based on syringe type, the market is segmented into luer lock syringes, glass syringes, luer slip syringes, and others. In 2019, the glass syringes segment held the largest share of the market. The segment is expected to grow at the fastest CAGR during the forecast period. This segment is likely to witness a lucrative growth owing to low mechanical tolerance, and smooth movement of the plunger. Furthermore, properties of glass, such as nonreactive nature and heat and chemical resistance, are contributing to the growth of this segment. Moreover, glass syringes are highly compatible with various drug filing devices and are easy to manufacture, which makes them the most preferred syringes in market. In March 2019, Gerresheimer AG launched metal free 1 ml long Luer lock Gx RTF glass syringes to deliver highly complex, protein-based bioengineered molecules.

In the last few years, the health care sector has witnessed SARS, H1N1 and other outbreaks. However, the severity of the coronavirus makes the situation more complex. Additionally, with no vaccine in market and only preventive measure to self-isolation is hitting the various industries including Syringe manufacturing in the region. The US and Canada have witnessed spike in cases in just few days, which has compelled the governments to shut down all the business in order to prevent the spread of the virus.. As of July 2020, in the US, more than 5.0 million confirmed corona cases were recorded and more than 160 thousands deaths were reported due to COVID 19 Pandemic. The syringe market is expected to be hit by the pandemic the most due to increasing number of cases and lockdown in most of the cities.

Becton, Dickinson and Company ; Baxter International Inc.; Terumo Corporation; Vita Needle Company; Cardinal Health Inc.; NIPRO; RETRACTABLE TECHNOLOGIES, INC.; B. Braun Medical Inc.; AIR-TITE PRODUCTS CO., INC.; and HENKE-SASS, WOLF Ltd., are among the leading companies operating in the syringes market.

Chronic diseases, such as diabetes, cardiovascular disease, and cancer, are among the primary causes of death in adults. Infectious diseases are also the top causes of death in children and adults. Chronic and infectious diseases need continuous diagnosis using various medical tests,which requires the use of syringes.

According to the World Health Organization estimations, around 16 billion injections are administered every year globally. It has been estimated that chronic diseases would account for almost three-quarters of all deaths worldwide, and that 75% of deaths due to stroke, 71% of deaths due to ischemic heart disease (IHD), and 70% of deaths due to diabetes would occur in developing countries by 2020. Many of these patients are advised regular intravenous administration of insulin, which increases the demand for syringes.

Infectious diseases are the secondtop cause of deaths worldwide and are among the top causes of death in children under age 5. For instance, the Centers for Disease Control and Prevention (CDC) stated that 1.7 million hospital-acquired infections (HAIs) occurred in 2017, and 99,000 associated deaths occur annually in American hospitals. It is estimated that nearly 32.0% of HAIs are urinary tract infections (UTIs), 22.0% are surgical site infections (SSIs), 15.0% are pneumonia, and 14.0% are bloodstream infections (BSIs).

Table of Contents

Report Overview: It includes the objectives and scope of the study and gives highlights of key market segments and players covered. It also includes years considered for the research study.

Executive Summary: It covers industry trends with high focus on market use cases and top market trends, market size by regions, and global market size. It also covers market share and growth rate by regions.

Key Players: Here, the report concentrates on mergers and acquisitions, expansions, analysis of key players, establishment date of companies, and areas served, manufacturing base, and revenue of key players.

Breakdown by Product and Application: This section provides details about market size by product and application.

Regional Analysis: All of the regions and countries analyzed in the report are studied on the basis of market size by product and application, key players, and market forecast.

Profiles of International Players: Here, players are evaluated on the basis of their gross margin, price, sales, revenue, business, products, and other company details.

Market Dynamics: It includes supply chain analysis, analysis of regional marketing, challenges,

Continued....

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services.

Contact Us:

The Insight partners,

Phone: +1-646-491-9876

Email: [email protected]

0 notes

silverlab101 · 2 years

Text

Extra Copd Resources

Therefore, treating tobacco use and dependence must be thought to be a major and particular intervention. Smoking ought to be routinely evaluated whenever a affected person presents to a healthcare facility and all smokers must be supplied one of the best chance to treat this disorder. COPD runs an insidious course, measured over years, with an usually undiagnosed preliminary part.

This is the quantity of air you can breathe out of the lungs in the first second of a forced expiration. It takes extra energy to breathe when you have COPD, so you may need to soak up more energy. But if you’re obese, your lungs and heart might have to work tougher. Limit caffeinated beverages as a result of they'll interfere with drugs. If you've heart problems, you could must drink less, so talk to your doctor. The long-acting bronchodilator can relax the airway muscle to assist the airways stay wider.

Inhaled corticosteroids are sometimes utilized in mixture with LABAs and LAMAs to decrease inflammation. A mixture of ICS and LABA has been proven to be more helpful than both of the drugs when used alone. Physicians and patients should respiratory disease treatment pay attention to an increased danger of growing pneumonia when handled with an ICS. Oral glucocorticoids usually are not indicated for long-term use and can have a number of unwanted effects.

Both are extra probably if you breathe secondhand smoke, or are exposed to chemicals or other fumes within the office. In bronchial asthma, the airway obstruction is reversible with inhaled medicines, however in COPD it's mostly fixed. The most common signs of COPD are breathlessness or a necessity for air, sputum manufacturing and a continual cough. Based on the area, the worldwide COPD treatment market segmentation is into Europe, Asia Pacific, North America, Middle East and Africa, and Latin America. According to a persistent obstructive pulmonary disease treatment trade analysis, North America accounted for the biggest revenue share of the worldwide market in 2021.

COPD can lead to symptoms similar to; fatigue and shortness of breath . Chronic Obstructive Pulmonary Disease can be used to describe a person with emphysema, persistent bronchitis, or a combination of the two. Infections are among the most typical causes of acute higher respiratory tract disease and occur most frequently through the fall and winter. Young children respiratory disease treatment might have as a lot as ten respiratory tract infections in a yr. Infections are usually triggered by respiratory viruses or, not often, micro organism. This can additionally be the explanation why antibiotics – which only work against micro organism – are often ineffective in treating acute upper respiratory tract infections and at worst can even be harmful.

Together, COPD and asthma ranked fourth in expenditures by situation, following heart conditions, trauma-related issues, and mental problems. Using the 2000 census inhabitants, this translates to an annual cost of almost $120 per individual respiratory disease treatment residing within the United States. It is projected that these prices will increase by 90% by the year 2020 . Antibiotics are an essential part of COPD treatment when infectious exacerbations occur, but are not recommended for long-term use.

Other life-style adjustments might embrace removing lung irritants from the house and workplace, in addition to learning how to save vitality throughout day by day activities. The patient may also have jerky actions because of buildup of carbon dioxide within the blood. It is not but understood what the function of air air pollution is in inflicting COPD. But working round giant amounts of assorted chemical fumes, similar to welding fumes, or numerous dusts, corresponding to mineral mud, might put you at higher greater threat of growing COPD. Protection from flu differs from all different vaccine-preventable diseases in that the organism changes from year-to-year, and due to this fact so should the vaccine .

0 notes

clevertimetravelpaper · 2 years

Text

Pneumonia Therapy Market competitive landscape, segmentation, global industry, market scope, market overview, revenue and forecast

Pneumonia therapeutics market is expected toto experience market growth during the forecast period from 2020 to 2027. Data Bridge Market Research analyzes that the market is growing at a healthy CAGR during the aforementioned research forecast period. The growing prevalence of the geriatric population is the factor responsible for the growth of the pneumonia therapeutics market. Pneumonia is an inflammatory medical condition that affects the air sacs and alveoli of the lungs. Pathogens such as bacteria, viruses, and fungi cause pneumococcal infection by inhaling airborne droplets from sneezing or coughing. Pneumonia can also be caused by touching objects and surfaces contaminated with bacteria and viruses that cause pneumonia.

Due to the increasing incidence of pneumococcal diseases and increasing level of environmental pollution, the initiation of preventive vaccination programs coupled with increased standards developed by healthcare institutions in the market are the driving factors. the growth of the pneumonia therapeutics market. However, increasing incidence rate of lung disorders in the world will drive the global pneumonia treatments market. However, lack of patient awareness and limited access to treatment may hamper the global pneumonia treatment market. Additionally, ongoing clinical trials for the development of vaccines and drug molecules provide opportunistic growth for the pneumonia therapeutics market.

Get Sample PDF of the Report – https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-pneumonia-therapeutics-market

Global Pneumonia Therapy Market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, research and development investments, new market initiatives, global presence, locations and production facilities, company strengths and weaknesses, product launch, clinical trial pipelines, product approvals, patents, product breadth and scope, application dominance, linear technology life curve . The data points provided above are only related to the companies' focus on the pneumonia therapeutics market. and Company, AstraZeneca, Pfizer Inc., Baxter International Inc., Allergan and Lupine Pharmaceuticals Inc. among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

This Pneumonia Therapeutics Market report provides details about recent new developments, trade regulations, import and export analysis, production analysis, value chain optimization, share of market, the impact of domestic and localized market players, analyzes opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growth, niches and dominance of applications, product approvals, product launches, geographic expansions, technological innovations in the market. For more insights on the Pneumonia Therapy Market, contact Data Bridge Market Research for an Analyst Brief,

To get more insights into Market Analysis, browse Research Report Summary @:– https://www.databridgemarketresearch.com/reports/global-pneumonia-therapeutics-market

Scope and Size of Pneumonia Therapy Market

The pneumonia therapeutics market is segmented on the basis of type, route of administration, end users and distribution channel. Growth between different segments helps you gain the knowledge related to the different growth factors expected to prevail in the market and formulate different strategies to help you identify the major application areas and differences between your target markets.

On the basis of type, the pneumonia therapeutics market is segmented into drugs, preventive vaccines and oxygen therapy. Based on route of administration, the pneumonia therapeutics market is segmented into oral, parenteral and others. On the basis of end users, the pneumonia therapeutics market is segmented into hospitals, specialty clinics, and others. Based on distribution channel, the pneumonia therapeutics market has also been segmented into hospital pharmacy, retail pharmacy, and others.

Country-Level Analysis of the Global Pneumonia Therapy Market

Global Pneumonia Therapeutics market is analyzed and market size information is provided by country, type, route of administration, end users and distribution channel as listed above. , Argentina, Peru, Rest of South America, In part of South America, Germany, France, United Kingdom, Netherlands, Switzerland, Belgium and Russia. , Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam , Rest of Asia Pacific, Saudi Arabia, Within Asia Pacific, United Arab Emirates, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, Middle East and Africa.

North America accounts for the largest market share owing to the presence of geriatric population and increase in healthcare facilities, which are the factors expected to drive the growth of the pneumonia treatments market. Asia-Pacific is expected to account for the largest market share in the coming years for the pneumonia treatments market due to the increase in the number of pharmaceutical and vaccine manufacturers in the region.

Browse Complete TOC at- https://www.databridgemarketresearch.com/toc/?dbmr=global-pneumonia-therapeutics-market

The country section of the report also provides individual market impact factors and regulatory changes in the national market that are impacting current and future market trends. Data points such as new sales, replacement sales, country demographics, disease epidemiology, and import-export tariffs are some of the major metrics used to forecast the market scenario for each country . In addition, the presence and availability of global brands and the challenges they face due to significant or rare competition from local and national brands, the impact of sales channels are considered while providing a forecast analysis of national data.